Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorthalidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 1.00 |
| ▸ | CA2 | P00918 | 9/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA3 | P07451 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CA4 | P22748 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorthalidone SCHEMBL4425734 | 1.00 | CA1 (1.00) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL164949 | 1.00 | CA1 (1.00) | CA1CA2CA7CA12CA3 | |
| (R)-Chlorthalidone SCHEMBL30872862 | 1.00 | CA1 (1.00) | CA1CA2CA7CA12CA3 | |
| (R)-Chlorthalidone SCHEMBL827454 | 1.00 | CA1 (1.00) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL29687442 | 1.00 | CA1 (1.00) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL28520875 | 0.99 | CA1 (0.98) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL7305527 | 0.95 | CA1 (0.91) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL29127388 | 0.92 | CA1 (0.84) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL28297372 | 0.86 | CA1 (0.73) | CA1CA2CA7CA12CA3 | |
| Chlorthalidone SCHEMBL4984545 | 0.86 | CA1 (0.73) | CA1CA2CA7CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21816 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743593-A1 | MATERIALS AND METHODS FOR DETERMINING GAIN OR LOSS OF MRNA TRANSCRIPTS | Ventana Medical Systems, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4744654-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122031485-A | Application of green relaxing muscles and tendons ketone in preparing medicine for treating rheumatoid disease | 南通大学 | 2026-05-15 | — | — | CN | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| EP-0011818-B1 | MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS BASED ON ALDOSTERONE ANTAGONISTS AND DIURETICS AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY AG (CH) | 1983-01-19 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4311697-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | claimed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | claimed |
| US-4261985-A | REDUCED EXCRETION OF POTASSIUM IONS BY INCLUSION OF ALDOSTERONE ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | claimed |
| US-4217347-A | MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | claimed |
| EP-0011818-A1 | Medicaments and pharmaceutical compositions based on aldosterone antagonists and diuretics and process for their manufacture | CIBA-GEIGY AG (CH) | 1980-06-11 | — | — | EP | claimed |
| US-4139633-A | ISOPROPYLAMINOPROPANE DERIVATIVES, SUBSTITUTED BENZENE SULPHONAMIDE | CIBA-GEIGY CORPORATION (US) | 1979-02-13 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |